Renal sodium-glucose transport: role in diabetes mellitus and potential clinical implications

被引:252
作者
Bakris, George L. [1 ]
Fonseca, Vivian A. [2 ]
Sharma, Kumar [3 ]
Wright, Ernest M. [4 ]
机构
[1] Univ Chicago, Hypertens Dis Unit, Dept Med, Pritzker Sch Med, Chicago, IL USA
[2] Tulane Univ, Hlth Sci Ctr, Dept Med & Pharmacol, New Orleans, LA 70118 USA
[3] Univ Calif San Diego VA Med Syst, Dept Med, La Jolla, CA USA
[4] Univ Calif Los Angeles, David Geffen Sch Med, Dept Physiol, Los Angeles, CA 90095 USA
基金
美国国家卫生研究院;
关键词
diabetes; glucose; glycosuria; hyperglycemia; kidney; transport; GLYCEMIC CONTROL; EXENATIDE EXENDIN-4; TREATED PATIENTS; SGLT2; INHIBITOR; LOW-AFFINITY; INSULIN; METFORMIN; COTRANSPORTERS; DAPAGLIFLOZIN; SULFONYLUREA;
D O I
10.1038/ki.2009.87
中图分类号
R5 [内科学]; R69 [泌尿科学(泌尿生殖系疾病)];
学科分类号
1002 ; 100201 ;
摘要
The kidneys play a major role in the regulation of glucose in humans, reabsorbing 99% of the plasma glucose that filters through the renal glomeruli tubules. The glucose transporter, SGLT2, which is found primarily in the S1 segment of the proximal renal tubule, is essential to this process, accounting for 90% of the glucose reabsorption in the kidney. Evidence has suggested that selective inhibition of SGLT2 induces glucosuria in a dose-dependent manner and may have beneficial effects on glucose regulation in individuals with type II diabetes. Preclinical data with SGLT2 inhibitors, such as dapagliflozin and sergliflozin, show that these compounds are highly selective inhibitors for SGLT2, have beneficial effects on the glucose utilization rate, and reduce hyperglycemia while having no hypoglycemic adverse effects. Clinical research remains to be carried out on the long-term effects of glucosuria and other potential effects of this class of drug. Nonetheless, these compounds represent a very promising approach for the treatment of diabetes. Kidney International ( 2009) 75, 1272-1277; doi:10.1038/ki.2009.87; published online 8 April 2009
引用
收藏
页码:1272 / 1277
页数:6
相关论文
共 27 条
  • [1] Improved diabetic syndrome in C57BL/KsJ-db/db mice by oral administration of the Na+-glucose cotransporter inhibitor T-1095
    Arakawa, K
    Ishihara, T
    Oku, A
    Nawano, M
    Ueta, K
    Kitamura, K
    Matsumoto, M
    Saito, A
    [J]. BRITISH JOURNAL OF PHARMACOLOGY, 2001, 132 (02) : 578 - 586
  • [2] Effects of exenatide (exendin-4) on glycemic control over 30 weeks in sulfonylurea-treated patients with type 2 diabetes
    Buse, JB
    Henry, RR
    Han, J
    Kim, DD
    Fineman, MS
    Baron, AD
    [J]. DIABETES CARE, 2004, 27 (11) : 2628 - 2635
  • [3] ANATOMICAL AND DEVELOPMENTAL PATTERNS OF FACILITATIVE GLUCOSE TRANSPORTER GENE-EXPRESSION IN THE RAT-KIDNEY
    CHIN, E
    ZHOU, J
    BONDY, C
    [J]. JOURNAL OF CLINICAL INVESTIGATION, 1993, 91 (04) : 1810 - 1815
  • [4] Effects of exenatide (exendin-4) on glycemic control and weight over 30 weeks in metformin-treated patients with type 2 diabetes
    DeFronzo, RA
    Ratner, RE
    Han, J
    Kim, DD
    Fineman, MS
    Baron, AD
    [J]. DIABETES CARE, 2005, 28 (05) : 1092 - 1100
  • [5] Glucagon-like peptides: Regulators of cell proliferation, differentiation, and apoptosis
    Drucker, DJ
    [J]. MOLECULAR ENDOCRINOLOGY, 2003, 17 (02) : 161 - 171
  • [6] Phlorizin: a review
    Ehrenkranz, JRL
    Lewis, NG
    Kahn, CR
    Roth, J
    [J]. DIABETES-METABOLISM RESEARCH AND REVIEWS, 2005, 21 (01) : 31 - 38
  • [7] Management of type 2 diabetes: Oral agents, insulin, and injectables
    Fonseca, Vivian A.
    Kulkarni, Karmeen D.
    [J]. JOURNAL OF THE AMERICAN DIETETIC ASSOCIATION, 2008, 108 (04) : S29 - S33
  • [8] Na+-glucose transporter-2 messenger ribonucleic acid expression in kidney of diabetic rats correlates with glycemic levels:: Involvement of hepatocyte nuclear factor-1α expression and activity
    Freitas, H. S.
    Anhe, G. F.
    Melo, K. F. S.
    Okamoto, M. M.
    Oliveira-Souza, M.
    Bordin, S.
    Machado, U. F.
    [J]. ENDOCRINOLOGY, 2008, 149 (02) : 717 - 724
  • [9] Gerstein HC, 2008, NEW ENGL J MED, V358, P2545, DOI 10.1056/NEJMoa0802743
  • [10] Dapagliflozin, a selective SGLT2 inhibitor, improves glucose homeostasis in normal and diabetic rats
    Han, Songping
    Hagan, Deborah L.
    Taylor, Joseph R.
    Xin, Li
    Meng, Wei
    Biller, Scott A.
    Wetterau, John R.
    Washburn, William N.
    Whaley, Jean M.
    [J]. DIABETES, 2008, 57 (06) : 1723 - 1729